Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract outlines a study evaluating dutasteride's effect on perioperative bleeding during transurethral resection of the prostate, but does not report any new clinical results.

In this case study, concurrent prostatic adenocarcinoma and a rare solitary fibrous tumor were identified on a transurethral resection of the prostate specimen.

The authors concluded that preoperative treatment with finasteride for a month effectively reduced perioperative bleeding and shortened hospital stays in patients undergoing transurethral resection of the prostate.

This study found that a substantial number of patients continued tamsulosin and/or finasteride unnecessarily after prostate surgery, with poor documentation and communication contributing to this issue.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

This study found that prescribing finasteride for two weeks before TURP surgery reduces intraoperative and postoperative blood loss, the rate of blood transfusion, and irrigation fluid usage in patients with BPH.

This study found that early treatment with estradiol or dihydrotestosterone significantly reduced prostate adenocarcinoma development in Lobund-Wistar rats, while later treatments were ineffective.

In this study, preoperative use of finasteride was associated with reduced blood loss and vascular endothelial growth factor expression during TURP, suggesting a potential benefit in preventing transurethral resection syndrome.

The study concluded that long-term finasteride pretreatment significantly reduces intraoperative and postoperative blood loss in patients undergoing transurethral resection of an enlarged prostate, whereas short-term pretreatment does not.

This study found that five years after prostatic surgery for male lower urinary tract symptoms associated with benign prostatic obstruction, 12% of patients required a second surgery, with prior prostatitis identified as a significant risk factor for reintervention.

This analysis concluded that preoperative finasteride significantly reduced blood loss during transurethral resection of the prostate by potentially decreasing the expression of VEGF and microvessel density.

This review discusses the role of finasteride preoperatively in reducing bleeding and complications during TURP and reports no new clinical results; the authors emphasize its potential benefits based on existing studies.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This clinical trial in Poland found that using finasteride, alone or with an alpha-blocker, reduced prostate adenoma size by 40% and improved micturition in patients with benign prostatic hyperplasia.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

Finasteride reduces bleeding risk during prostate surgery.

This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.

This review discusses the impact of various treatments for prostate cancer, noting that while 5α-reductase inhibitors reduce risk, they may not decrease and could even increase high-risk cancers; the authors highlight that recent data suggest longer screening can reduce prostate cancer mortality more effectively.

Finasteride may reduce prostate cancer risk.

This study found that finasteride administration for more than one month before TURP surgery significantly reduces blood loss in patients with benign prostatic hyperplasia.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

A bladder rupture from prostate treatment was healed with catheterization and antibiotics.